Russia’s flagship two-shot vaccine Sputnik V has shown 91.6 per cent efficacy against symptomatic Covid-19 in clinical trials, a Lancet peer review has confirmed, bringing the global total of vaccines whose efficacy is confirmed to be higher than 90 per cent to three.
The results from an interim analysis, now confirmed by peer review, also showed the jab provided full protection against moderate or severe cases of Covid-19.
Alexander Gintsburg, director of Russia’s Gamaleya Institute, the state-run virology research centre that developed the jab, said the results were a “monumental achievement” and “a great success in the battle against the global Covid-19 pandemic”.
您已閱讀21%（673字），剩余79%（2554字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。